Article info
PDFOriginal research
Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
- Correspondence to Laura Salinas-Ortega, Pharmacoeconomics and Outcomes Research Iberia, Pozuelo de Alarcón 28224, Spain; lsalinas{at}porib.com
Citation
Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain
Publication history
- Received July 8, 2021
- Accepted November 1, 2021
- First published November 22, 2021.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2021. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.